QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System

August 30, 2011

QLT Inc. yesterday announced results of its Phase II clinical study on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG).

The results were promising with the study representing the first reported demonstration of a clinically significant, prolonged (4 weeks) reduction in intraocular pressure (IOP) in glaucoma with an  extraocular, minimally-invasive sustained release ophthalmic drug delivery system.

Click here for the full release.




Jump down to form below to submit your own comments

Comments are closed.